This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

New Biomarkers & Endpoints in HBV | Room 716

Thursday, June 14, 2018
4:15 PM to 6:00 PM

Chairs: Blaine Hollinger & Seng Gee Lim

Invited Presentations:


The value of HBsAg quantification in the natural history and treatment of HBV Henry Chan, The Chinese University Of Hong Kong, Hong Kong

Choosing the right endpoint for HBV treatment Jean Michel Pawlotsky, Henri Mondor University Hospital, Creteil

New Biomarkers for HBV infection Harry Janssen, Toronto Centre for Liver Disease, Toronto

Oral Abstracts:

Utility of a new HBV RNA assay in HBeAg positive and negative CHB and following HBsAg seroclearance in patients treated with ARC-520, an RNAi drug targeting cccDNA derived HBV mRNA Emily Butler, Abbott Diagnostics, Chicago

HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B and its relation to other serum viral biomarkers Mina Farag, Toronto Center For Liver Disease, Toronto